股息配發率   玩股撇步(動畫小學堂)

  • 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: 75.23%
  • 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
  • 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY現金股利 YoY股票股利 YoY現金配發率 YoY股票配發率 YoY全部配發率 YoY
2023 (10)-1.2000.0000.0000.0000.0000.000
2022 (9)-0.0800.0000.0000.0000.0000.000
2021 (8)1.9922.091.3523.850.00067.841.450.00067.841.45
2020 (7)1.63-37.311.0911.220.00066.8777.410.00066.8777.41
2019 (6)2.60162.630.9811.360.00037.69-57.60.00037.69-57.6
2018 (5)0.99-22.660.88-40.140.00088.89-22.60.00088.89-22.6
2017 (4)1.28-29.281.47-26.50.000114.843.930.000114.843.93
2016 (3)1.8119.082.0017.650.000110.50-1.20.000110.50-1.2
每股盈餘-近20季
EPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY
23Q4 (20)-0.2543.1826.47-0.1772.5841.38-1.20-26.32-1400.0
23Q3 (19)-0.44-29.41-450.0-0.62-63.16-195.24-0.95-86.27-451.85
23Q2 (18)-0.34-100.0-409.09-0.38-123.53-575.0-0.51-200.0-245.71
23Q1 (17)-0.1750.0-170.83-0.1741.38-241.67-0.17-112.5-170.83
22Q4 (16)-0.34-325.0-180.95-0.29-38.1-176.32-0.08-129.63-103.96
22Q3 (15)-0.08-172.73-111.76-0.21-362.5-131.340.27-22.86-83.12
22Q2 (14)0.11-54.17-77.550.08-33.33-87.10.3545.83-61.96
22Q1 (13)0.24-42.86-44.190.12-68.42-68.420.24-88.12-44.19
21Q4 (12)0.42-38.2435.480.38-43.28-9.522.0226.2520.96
21Q3 (11)0.6838.78-21.840.678.06-19.281.6073.9117.65
21Q2 (10)0.4913.9528.950.6263.166.90.92113.9587.76
21Q1 (9)0.4338.71290.910.38-9.52375.00.43-74.25290.91
20Q4 (8)0.31-64.37520.00.42-49.4147.061.6722.79-37.92
20Q3 (7)0.87128.9564.150.8343.143.11.36177.55-48.68
20Q2 (6)0.38245.45-70.540.58625.0825.00.49345.45-76.89
20Q1 (5)0.11120.0-86.90.08-52.94121.050.11-95.91-86.9
19Q4 (4)0.05-90.570.00.17-70.690.02.691.510.0
19Q3 (3)0.53-58.910.00.58825.00.02.6525.00.0
19Q2 (2)1.2953.570.0-0.0878.950.02.12152.380.0
19Q1 (1)0.840.00.0-0.380.00.00.840.00.0
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2024/30.1615.4722.340.457.310.45N/A-
2024/20.14-6.28-3.840.290.420.46N/A-
2024/10.15-12.724.780.154.780.47N/A-
2023/120.1710.587.281.61-31.660.451.45-
2023/110.1524.533.131.44-34.470.391.67-
2023/100.1211.41-13.191.29-38.230.371.74-
2023/90.11-20.68-17.241.16-40.060.361.51-
2023/80.1423.4-11.591.05-41.760.371.47-
2023/70.11-5.88-40.940.91-44.650.361.54-
2023/60.12-1.58-32.240.8-45.140.381.57-
2023/50.12-11.36-40.790.68-46.940.391.53-
2023/40.145.09-58.150.56-48.130.411.45業績衰退,因客戶庫存水位仍高且中國受美經濟制裁,外銷訂單銳減,導致訂單及出貨延遲。
2023/30.13-9.24-41.910.42-43.670.421.48-
2023/20.142.13-45.390.29-44.440.451.39-
2023/10.14-10.64-43.440.14-43.440.421.49-
2022/120.1637.23-41.982.36-46.060.421.61-
2022/110.12-18.82-65.072.2-46.330.391.71高通膨壓抑全球消費力道,消費性產品尤為嚴重,加上代理商庫存水位高,影響出貨。
2022/100.146.22-61.832.08-44.690.431.54高通膨壓抑全球消費力道,消費性產品尤為嚴重,加上中國不斷封控及代理商庫存水位高,影響出貨。
2022/90.13-15.27-65.291.94-42.80.481.59高通膨壓抑全球消費力道,消費性產品尤為嚴重,加上中國不斷封控及代理商庫存水位高,影響出貨。
2022/80.16-17.56-61.241.81-39.910.531.46高通膨壓抑全球消費力道,消費性產品尤為嚴重,加上中國不斷封控及代理商庫存水位高,影響出貨。
2022/70.197.97-49.531.65-36.560.581.34-
2022/60.18-14.0-58.01.46-34.340.710.95高通膨壓抑消費力道,全球經濟活動放緩,消費性產品遭上游客戶砍單,加上中國封城影響,代理商庫存水位高,工廠停滯,影響出貨。
2022/50.21-37.35-45.651.28-28.760.760.89-
2022/40.3345.87-8.311.07-24.220.820.83-
2022/30.23-14.69-29.950.74-29.640.740.94-
2022/20.275.8-16.550.52-29.510.790.89-
2022/10.25-8.34-39.450.25-39.450.860.82-
2021/120.27-17.3813.684.37-6.410.980.73-
2021/110.33-11.27-22.484.1-7.51.090.65-
2021/100.37-3.42-11.593.77-5.91.170.61-
2021/90.39-5.38-10.453.39-5.231.180.47-
2021/80.417.33-3.533.01-4.521.210.45-
2021/70.38-10.14-27.542.6-4.671.180.46-
2021/60.4211.28-20.522.220.781.160.54-
2021/50.385.69-12.181.87.581.060.59-
2021/40.3611.44-11.821.4114.511.00.63-
2021/30.321.61-29.281.0527.511.050.76-
2021/20.32-23.2365.620.7397.530.970.82去年2月因受新冠肺炎影嚮,大陸客戶及加工廠復工率低,無法正常出貨,今年2月年後準時開工,且出貨正常,故較去年營收成長
2021/10.4172.1131.810.41131.811.080.741月份營收增加之原因為受2月份農曆春節假期影響工作天數減少,客戶需求提前於1月份出貨。
2020/120.24-43.67-23.354.6717.081.090.81-
2020/110.431.1716.314.4320.531.280.69-
2020/100.42-2.1741.774.021.01.280.69-
2020/90.431.9323.243.5818.951.380.64-
2020/80.42-19.38-13.353.1518.381.480.59-
2020/70.53-1.4257.972.7325.531.490.59因疫情持續升溫,本公司健康醫療系列產品體溫計IC熱賣及優化產品組合,故營收較去年同期大幅成長。
2020/60.5322.9555.942.219.661.370.59因疫情持續升溫,本公司健康醫療系列產品體溫計IC熱賣,故營收較去年同期大幅成長。
2020/50.436.128.221.6711.391.30.62-
2020/40.41-10.6114.651.2412.551.060.77-
2020/30.46137.9832.080.8311.530.830.98-
2020/20.197.4418.650.37-6.40.681.18-
2020/10.18-43.09-23.710.18-23.710.860.94-
2019/120.31-14.5249.443.998.840.980.62-
2019/110.3723.33-1.713.686.371.010.6-
2019/100.3-14.96-1.053.317.351.140.54-
2019/90.35-28.3435.693.018.261.170.6-
2019/80.4946.9957.92.665.451.160.67月份訂單因產能來不及交貨故延至8月份交貨,部份9月初訂單也提前在8月份交貨,故造成營收成長。
2019/70.33-2.69-0.962.17-1.871.070.65-
2019/60.34-14.663.421.84-2.031.10.7-
2019/50.412.4321.011.5-3.20.0N/A-
2019/40.362.964.01.1-9.780.0N/A-

其它人也看了

股利相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。